Positive Data For Amgen/UCB's Romosozumab In Men With Osteoporosis

Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.

Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.

"While the focus of managing osteoporosis is often on women, osteoporosis in men is also a serious health issue," said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category